RecruitingPhase 1Phase 2NCT06525636
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
A Multicenter, Open-label, Phase 1/2, Dose-escalation and Subsequent Safety Extension Study of Subcutaneous KK8123 in Adult Patients With X-linked Hypophosphatemia
Sponsor
Kyowa Kirin Co., Ltd.
Enrollment
24 participants
Start Date
Oct 9, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called KK8123 for people with x-linked hypophosphatemia. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years to 65 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGKK8123
Subcutaneous administration
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06525636